Status:
COMPLETED
Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Naturalistic
Observational
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in Korean Bipolar patients.
Eligibility Criteria
Inclusion
- The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent.
- Meet DSM-IV-TR criteria for bipolar disorder (bipolar I disorder, bipolar II disorder) at the time of baseline.
Exclusion
- Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history.
- Known intolerance for or lack of response to atypical antipsychotics , as judged by the investigator.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00745966
Start Date
July 1 2008
Last Update
October 6 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Kyunggi-do, Choonchun-si, South Korea
2
RFesearch Site
Daegu, Joong-gu, South Korea